Mesenchymal stem cell therapy may lowdown the progression and sheal osteoarthritis and musculoskeletal disease

Primary tabs

Mesenchymal stem cell therapy may lowdown the progression and sheal osteoarthritis and musculoskeletal disease

Researchers hope that they have finally found a key to osteoarthritis (OA) treatment with the help of  mesenchymal stem cells which can offer a potent way to slow down the progression and repair degenerative signs of the disease Researchers have shed light on stem cell therapy for OA  and supported its use in the clinical setting for the joint pain.

Johnny Huard, Ph.D., distinguished professor & vice chairman for research, Department of Orthopaedic Surgery, University of Texas Health System, Houston, Texas, revealed that MDSCs improves the tissue repair through a paracrine effect that consists angiogenesis.

Angiogenesis plays a vital role in repair of tissues such as articular cartilage repair and healing related to OA. Dr. Huang discussed the data about preclinical animal studies which cited that blocking angiogenesis is critical to repairing articular cartilage in OA. Particularly, murine studies have revealed that injecting a particular type of stem cell (MDSC-sFlt-1/BMP4) confers the best repair of articular cartilage after OA. A study by Kubo et al. have shown that blocking angiogenesis in humans also improved the regenerative capacity of adult-derived stem cells for repair of the articular cartilage after injury.

In addition to this, it was found that by injecting young stem cells into mice extends their lifespan(longer and healthier). Although its exact mechanism is still not known, it is likely to depend on the secretion of growth factors that promote angiogenesis. Some of the preclinical data showed MDSCs benefits in mouse studies and emphasized that transferring these results to humans is a different feat. It is somewhat easy to deal and mice, but treating humans with cells requires a team approach to address the myriad issues of using a cell therapy that may change behavior once injected into a body.

Additionally, Christian Jorgensen and his team members assessed the safety of injecting autologous adipose-derived stromal cells (ASCs) in 18 patients to treat severe knee OA. In phase - clinical trial, patients were divided into three cohorts (50 patients in each) treated with low dose (2×106 cells), medium dose (10×106 cells) and high dose (50×106 cells). The low-dose group had a significantly better performance than those in the high-dose group had up to one year of clinical efficacy. They also found some patients failed to respond to this treatment while some the patients exhibited best results.

Based upon these findings, an ongoing phase II study is currently assessing (150 patients) with severe knee OA treated with autologous stem cells over the next year. Dr. Jorgensen pointed out that a myriad of studies using allogenic stem cells were being done with promising results with very similar responses in terms of safety and efficacy to autologous stem cells and given their reduced production costs. Further, Dr. Jorgensen described the results of a pilot study that evaluated feasibility and safety of 10 patients with chronic back pain diagnosed with lumbar disc degeneration treated with mesenchymal stem cells.  The results of this phase I trial already showed that pain and function could be improved in these patients.

Thus, researchers drew attention towards the current clinical data which are encouraging and confirm the positive results, while more work remains to be done on the potency of the cells after injection and improving how cells are produced to help in reducing the cost. However, further long-term randomized controlled trials are necessary to determine its benefits.


The Rheumatologist

Link to the source:

The original title of the article:

Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease

Therapeutic, Osteoarthritis, Joints, Efficacy, Safety
Log in or register to post comments